Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 923-930

  Kurajoh, M ^a   Inaba, M ^a   Okuno, S ^a   Nagayama, H ^a   Yamada, S ^a   Imanishi, Y ^a   Ishimura, E ^a   Shoji, S ^a   Yamakawa, T ^a   Nishizawa, Y ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marker; Cinacalcet; Intact PTH; PTH(1 84); PTH(7 84) like fragment; Whole PTH

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CINACALCET; PARATHYROID HORMONE; PROTEIN TRAP5B; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD LEVEL; BONE METABOLISM; CLINICAL ARTICLE; DEPRESSION; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMODIALYSIS; HUMAN; HYPOCALCEMIA; MALE; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; VOMITING;

ACID PHOSPHATASE; ADULT; AGED; BONE REMODELING; CALCIUM; COLLAGEN TYPE I; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; ISOENZYMES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PEPTIDES; PHOSPHORUS; RENAL DIALYSIS; UREMIA;

EID: 79951669785     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1262-x     Document Type: Article

References (32)

1. T Kawata Y Imanishi K Kobayashi T Kenko M Wada E Ishimura T Miki N Nagano M Inaba A Arnold Y Nishizawa 2005 Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism Eur J Endocrinol 153 587 594 1:CAS:528: DC%2BD2MXhtFygsb7I 10.1530/eje.1.02007 16189180 (Pubitemid 41556286)
2. GA Block KJ Martin AL de Francisco SA Turner MM Avram MG Suranyi G Hercz J Cunningham AK Abu-Alfa P Messa DW Coyne F Locatelli RM Cohen P Evenepoel SM Moe A Fournier J Braun LC McCary VJ Zani KA Olson TB Drueke WG Goodman 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516 1525 1:CAS:528:DC%2BD2cXjtVeqtLY%3D 10.1056/NEJMoa031633 15071126 (Pubitemid 38477776)
3. SM Moe J Cunningham J Bommer S Adler SJ Rosansky P Urena-Torres MB Albizem MD Guo VJ Zani WG Goodman SM Sprague 2005 Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl Nephrol Dial Transplant 20 2186 2193 1:CAS:528:DC%2BD2MXhtVWntL7O 10.1093/ndt/gfh966 16030053 (Pubitemid 41510096)
4. P Messa F Macario M Yaqoob K Bouman J Braun B von Albertini H Brink F Maduell H Graf JM Frazao WJ Bos V Torregrosa H Saha H Reichel M Wilkie VJ Zani B Molemans D Carter F Locatelli 2008 The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism Clin J Am Soc Nephrol 3 36 45 1:CAS:528:DC%2BD1cXhs1eitL8%3D 10.2215/CJN.03591006 18178780
5. JS Lindberg B Culleton G Wong MF Borah RV Clark WB Shapiro SD Roger FE Husserl PS Klassen MD Guo MB Albizem JW Coburn 2005 Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800 807 1:CAS:528:DC%2BD2MXis12nsr4%3D 10.1681/ASN.2004060512 15689407 (Pubitemid 41725117)
6. T Kawata Y Imanishi K Kobayashi N Onoda Y Takemoto H Tahara S Okuno E Ishimura T Miki T Ishikawa M Inaba Y Nishizawa 2005 Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells J Clin Endocrinol Metab 90 5774 5778 1:CAS:528:DC%2BD2MXhtFWjt7vE 10.1210/jc.2005-0243 16046589 (Pubitemid 41415491)
7. Y Imanishi T Kawata K Kobayashi M Wada N Onoda Y Takemoto S Okuno H Tahara E Ishimura T Ishikawa N Nagano T Miki M Inaba Y Nishizawa 2007 Stimulation of calcium-sensing receptor truncate human (1-84) parathyroid hormone amino-terminally in vitro by human parathyroid cells J Am Soc Nephrol 18 Abstract Issue 753A (Abstract no. SU-PO764)
8. M Inaba S Okuno Y Imanishi M Ueda T Yamakawa E Ishimura Y Nishizawa 2005 Significance of bio-intact PTH(1-84) assay in hemodialysis patients Osteoporos Int 16 517 525 1:CAS:528:DC%2BD2MXlsFSrsrw%3D 10.1007/s00198-004-1715-1 15322741
9. M Kurajoh M Inaba S Yamada Y Imanishi T Tsuchida E Ishimura Y Nishizawa 2008 Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D Osteoporos Int 19 709 716 1:CAS:528:DC%2BD1cXktV2jtb8%3D 10.1007/s00198-007-0554-2 18239958
10. KJ Martin H Juppner DJ Sherrard WG Goodman MR Kaplan G Nassar P Campbell M Curzi C Charytan LC McCary MD Guo SA Turner DA Bushinsky 2005 First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl Kidney Int 68 1236 1243 1:CAS:528:DC%2BD2MXhtVCjt7rO 10.1111/j.1523-1755.2005.00517.x 16105056 (Pubitemid 43246442)
11. K Shidara M Inaba S Okuno S Yamada Y Kumeda Y Imanishi T Yamakawa E Ishimura Y Nishizawa 2008 Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients Calcif Tissue Int 82 278 287 1:CAS:528: DC%2BD1cXlt1Cqtb4%3D 10.1007/s00223-008-9127-4 18421493
12. M Inaba M Terada Y Nishizawa A Shioi E Ishimura S Otani H Morii 1999 Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism Metabolism 48 904 909 1:CAS:528:DyaK1MXksFOru70%3D 10.1016/S0026-0495(99)90227-5 10421234 (Pubitemid 29310048)
13. E Ishimura Y Nishizawa M Inaba N Matsumoto M Emoto T Kawagishi S Shoji S Okuno M Kim T Miki H Morii 1999 Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure Kidney Int 55 1019 1027 1:STN:280:DyaK1M7lt1ahtw%3D%3D 10.1046/j.1523-1755.1999.0550031019.x 10027939 (Pubitemid 29100714)
14. M Inaba Y Nishizawa K Mita Y Kumeda M Emoto T Kawagishi E Ishimura K Nakatsuka A Shioi H Morii 1999 Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes Osteoporos Int 9 525 531 1:CAS:528:DyaK1MXlslSlt74%3D 10.1007/s001980050180 10624460 (Pubitemid 29348568)
15. Y Kumeda M Inaba H Tahara Y Kurioka T Ishikawa H Morii Y Nishizawa 2000 Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism J Clin Endocrinol Metab 85 4157 4161 1:CAS:528: DC%2BD3cXotlWnurY%3D 10.1210/jc.85.11.4157 11095447 (Pubitemid 32055367)
16. T Ohashi Y Igarashi Y Mochizuki T Miura N Inaba K Katayama T Tomonaga F Nomura 2007 Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b Clin Chim Acta 376 205 212 1:CAS:528:DC%2BD28XhtlaltbbL 10.1016/j.cca.2006.08.021 17045980 (Pubitemid 44889255)
17. BJ Gertz JD Clemens SD Holland W Yuan S Greenspan 1998 Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment Calcif Tissue Int 63 102 106 1:CAS:528:DyaK1cXkvFWnu7w%3D 10.1007/s002239900497 9685512 (Pubitemid 28347681)
18. JD Clemens MV Herrick FR Singer DR Eyre 1997 Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption Clin Chem 43 2058 2063 1:CAS:528:DyaK2sXnt1ejs7Y%3D 9365389 (Pubitemid 27497803)
19. B Gomez Jr S Ardakani J Ju D Jenkins MJ Cerelli GY Daniloff VT Kung 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum Clin Chem 41 1560 1566 1:CAS:528:DyaK2MXpt1Onurk%3D 7586543
20. P Gao S Scheibel P D'Amour MR John SD Rao H Schmidt-Gayk TL Cantor 2001 Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function J Bone Miner Res 16 605 614 1:CAS:528:DC%2BD3MXislCksbg%3D 10.1359/jbmr.2001.16.4.605 11315988 (Pubitemid 32230589)
21. MR John WG Goodman P Gao TL Cantor IB Salusky H Juppner 1999 A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure J Clin Endocrinol Metab 84 4287 4290 1:CAS:528:DyaK1MXntlyjs7c%3D 10.1210/jc.84.11.4287 10566687 (Pubitemid 30644232)
22. JC Souberbielle A Boutten MC Carlier D Chevenne G Coumaros E Lawson-Body C Massart M Monge J Myara X Parent E Plouvier P Houillier 2006 Inter-method variability in PTH measurement: implication for the care of CKD patients Kidney Int 70 345 350 1:CAS:528:DC%2BD28XmvFagtro%3D 10.1038/sj.ki.5001606 16788691 (Pubitemid 44086584)
23. R Lepage L Roy JH Brossard L Rousseau C Dorais C Lazure P D'Amour 1998 A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples Clin Chem 44 805 809 1:CAS:528:DyaK1cXisFSitr0%3D 9554492 (Pubitemid 28176023)
24. M Inaba K Nakatsuka Y Imanishi M Watanabe Y Mamiya E Ishimura Y Nishizawa 2004 Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone Clin Chem 50 385 390 1:CAS:528:DC%2BD2cXhtFKktb4%3D 10.1373/clinchem.2003.026831 14684623 (Pubitemid 38156380)
25. H Reichel A Esser HJ Roth H Schmidt-Gayk 2003 Influence of PTH assay methodology on differential diagnosis of renal bone disease Nephrol Dial Transplant 18 759 768 1:CAS:528:DC%2BD3sXit1yqsr0%3D 10.1093/ndt/gfg144 12637646 (Pubitemid 36432259)
26. HJ Roth 2000 Elecsys parathyroid hormone (PTH) not detecting the large PTH fragment hPTH (7-84)? Clin Lab 46 295 299 1:STN:280:DC%2BD3M%2Fis1KrsA%3D%3D 10853240 (Pubitemid 30326156)
27. Y Hiroyuki Y Motomiya K Uchida T Akizawa 2002 Development and clinical application of whole PTH (PTH1-84) kit Jpn J Med Pharm Sci 48 243 247
28. K Inomata H Yamashita A Yamamoto M Yukishita M Adachi 2004 Influence of 25-hydroxyvitamin D concentration on the reference range of intact PTH Osteoporosis Jpn 12 449 456
29. S Yamada M Inaba M Kurajoh K Shidara Y Imanishi E Ishimura Y Nishizawa 2008 Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction Clin Endocrinol 69 189 196 1:CAS:528:DC%2BD1cXhtVarsL7M 10.1111/j.1365-2265.2008.03187.x (Pubitemid 352009021)
30. A Yajima M Inaba Y Ogawa Y Tominaga T Tanizawa T Inou O Otsubo 2007 Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism Nephrol Dial Transplant 22 1645 1657 1:CAS:528:DC%2BD2sXot1Sgs7Y%3D 10.1093/ndt/gfl837 17307749 (Pubitemid 47073764)
31. A Yajima M Inaba Y Tominaga A Ito 2008 Bone formation by minimodeling is more active than remodeling after parathyroidectomy Kidney Int 74 775 781 10.1038/ki.2008.242 18528319
32. M Peacock JP Bilezikian PS Klassen MD Guo SA Turner D Shoback 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism J Clin Endocrinol Metab 90 135 141 1:CAS:528:DC%2BD2MXlvFelsQ%3D%3D 10.1210/jc.2004-0842 15522938 (Pubitemid 40116646)